Bogsrud 2013.
Methods | 6‐Week wash‐out period 4‐Week before‐and‐after study |
|
Participants | 41 men and women aged 18 to 75 years with hypercholesterolaemia Exclusion criteria: serious adverse events during previous statin therapy, liver or kidney failure, individuals taking concomitant medication that would interfere with the study Atorvastatin baseline TC: 7.17 mmol/L (277 mg/dL) Atorvastatin baseline LDL‐C: 5.18 mmol/L (200 mg/dL) Atorvastatin baseline HDL‐C: 1.49 mmol/L (57.6 mg/dL) Atorvastatin baseline TG: 1.67 mmol/L (148 mg/dL) |
|
Interventions | Atorvastatin 10 mg/d | |
Outcomes | Per cent change from baseline at 4 weeks of serum TC, LDL‐C, HDL‐C and TG | |
Notes | SDs were imputed | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Atorvastatin 10 mg/d; treatment intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable |
Allocation concealment (selection bias) | Unclear risk | Atorvastatin 10 mg/d; treatment intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable |
Blinding (performance bias and detection bias) All outcomes | Unclear risk | Atorvastatin 10 mg/d; treatment intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Data on all participants were reported |
Selective reporting (reporting bias) | Low risk | All lipid parameters were measured |
Other bias | Low risk | The study was funded by Pharma Nord ApS, which does not market statins of any kind |